Preablation stimulated thyroglobulin is a good predictor of successful ablation in patients with differentiated thyroid cancer

Clinical Nuclear Medicine

Volumn 37, Issue 6, 2012, Pages 545-549

  Kendler, Daniel B ^a   Vaisman, Fernanda ^a   Corbo, Rossana ^a   Martins, Rosĝngela ^a   Vaisman, Mario ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

prognostic factors; radioiodine remnant ablation; thyroglobulin; well differentiated thyroid carcinoma

Indexed keywords

RADIOACTIVE IODINE; THYROGLOBULIN;

ABLATION THERAPY; ADULT; AGED; CANCER STAGING; DIFFERENTIATED THYROID CANCER; DISTANT METASTASIS; FEMALE; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; REVIEW; THYROGLOBULIN BLOOD LEVEL;

ABLATION TECHNIQUES; ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SEX FACTORS; THYROGLOBULIN; THYROID HORMONES; THYROID NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 84861439513     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31824852f8     Document Type: Review

References (32)

1. Cooper DS, Doherty GM, Haugen BR, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
2. Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787-803. (Pubitemid 43997716)
3. Maia AL, Ward LS, Carvalho GA, et al. Thyroid nodules and differentiated thyroid cancer: Brazilian consensus. Arqua Bras Endocrinol Metab. 2007;51:867-893.
4. Podnos YD, Smith DD, Wagman LD, et al. Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope. J Surg Oncol. 2007;96:3-7. (Pubitemid 47015441)
5. Van Nostrand D, Wartofsky L. Radioiodine in the treatment of thyroid cancer. Endocrinol Metab Clin North Am. 2007;36:807-822. (Pubitemid 47126256)
6. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-1463. (Pubitemid 32374886)
7. Cailleux AF, Baudin E, Travagli JP, et al. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab. 2000;85:175-178. (Pubitemid 32268810)
8. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab. 2002;87: 1490-1498. (Pubitemid 34615227)
9. Ronga G, Filesi M, Ventroni G, et al. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med. 1999;26: 1448-1452. (Pubitemid 29515606)
10. Hall FT, Beasley NJ, Eski SJ, et al. Predictive value of serum thyroglobulin after surgery for thyroid carcinoma. Laryngoscope. 2003; 113:77-81. (Pubitemid 36050517)
11. Ruiz-Garcia J, Ruiz de Almodóvar JM, Olea N, et al. Thyroglobulin level as a predictive factor of tumoral recurrence in differentiated thyroid cancer. J Nucl Med. 1991;32:395-398.
12. Rosário PW, Guimarães VC, Maia FF, et al. Thyroglobulin before ablation and correlation with posttreatment scanning. Laryncoscope. 2005;115: 264-267. (Pubitemid 40216700)
13. Hackshaw A, Harmer C, Mallick U, et al. 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab. 2007;92:28-38. (Pubitemid 46075005)
14. Bachelot A, Cailleux AF, Klain M, et al. Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid. 2002;12:707-711. (Pubitemid 34913243)
15. Toubeau M, Touzery C, Arveux P, et al. Predictive value of disease progression of serum thyroglobulin levels measured in the postoperative period and after 131I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med. 2004;45:988-994. (Pubitemid 47611686)
16. Kim TY, Kim WB, Kim ES, et al. Serum thyroglobulin level at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:1440-1445.
17. Bernier MO, Morel O, Rodien P, et al. Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2005;32:1418-1421. (Pubitemid 41746846)
18. Lee HJ, Rha SY, Jo YS, et al. Predictive value of the preablation serum thyroglobulin level after thyreoidectomy is combined with postablation 131I whole body scintigraphy for successful ablation in patients with differentiated thyroid carcinoma. Am J Clin Oncol. 2007;30:63-68. (Pubitemid 46213827)
19. Heemstra KA, Liu KY, Stokkelt M, et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol. 2007;66:58-64. (Pubitemid 44952495)
20. Giovanella L, Ceriani L, Suriano S, et al. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma. Clin Endocrinol. 2008;69:659-663.
21. Verburg FA, Keizer B, Lips CJ, et al. Prognostic significance of good response to initial therapy with radioiodine of differentiated thyroid cancer patients. Eur J Endocrinol. 2005;152:33-37. (Pubitemid 40185450)
22. Golger A, Fridman TR, Eski S, et al. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/ recurrent well-differentiated thyroid carcinoma. J Endocrinol Invest. 2003; 26:1023-1031. (Pubitemid 38049156)
23. Vaisman A, Orlov S, Yip J, et al. Appplication of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. Head Neck. 2010;32:689-698.
24. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050-1058. (Pubitemid 24004722)
25. Karam M, Feustel PJ, Postal ES, et al. Successful thyroid tissue ablation as defined by a negative whole-body scan or an undetectable thyroglobulin: a comparative study. Nucl Med Commun. 2005;26:331-336. (Pubitemid 40460526)
26. Rosário PW, Barroso AL, Rezende LL, et al. Outcome of ablation of thyroid remnants with 100 mCi (3.7 GBq) iodine-131 in patients with thyroid cancer. Ann Nucl Med. 2005;19:247-250. (Pubitemid 40874520)
27. Rosário PW, Reis JS, Barroso AL, et al. Efficacy of low and high 131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake. Nucl Med Commun. 2004;25:1077-1081. (Pubitemid 39488938)
28. De Klerk J, De Keizer B, Zelissen P, et al. Fixed dosage of I131 for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic I131 scintigraphy. Nucl Med Commun. 2000;21:529-532.
29. Chianelli M, Todino V, Graziano FM, et al. Low activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in lowrisk patients. Eur J Endocrinol. 2009;160:431-436.
30. Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2002;87:4063-4068.
31. Pacini F, Landenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized controlled study. J Clin Endocrinol Metab. 2006;91:926-932. (Pubitemid 43357760)
32. Pacini F, Capezzone M, Elisei R, et al. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab. 2002;87:1499-1501. (Pubitemid 34615228)